Adagio Collaborates with Biocon to Provide COVID-19 Ab Treatment to Patients in India and Other Emerging Markets

Shots:

  • The companies collaborated for Adagio’s ADG20 for both the treatment & prevention of COVID-19 as monothx. or combination regimen
  • Biocon will gain rights to manufacture & commercialize ADG20 for COVID-19 in India and select emerging markets based on the commercial process developed for ADG20. The company will have the access to Adagio’s ongoing P-II/III study data & to its anticipated EUA along with regulatory submissions, supporting the approval or EUA in India & other emerging markets
  • ADG20 is currently being evaluated in two studies. The STAMP trial to evaluate ADG20 for non-hospitalized COVID-19 patients and the EVADE trial to evaluate ADG20 for the prevention of COVID-19

Click here to­ read full press release/ article | Ref: Businesswire | Image: Adagio

The post Adagio Collaborates with Biocon to Provide COVID-19 Ab Treatment to Patients in India and Other Emerging Markets first appeared on PharmaShots.